The trial participants will have been constrained during the trial to opt for alternative treatments.
With the conclusion of the Anavax trial, that constraint should be lifted, and the trial participants should be able to have access to NEU's Trofinetide, with its demonstrable patient benefits.
The trial participants will have been constrained during the...
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.47 |
Change
-1.120(7.18%) |
Mkt cap ! $1.849B | |||
| Open | High | Low | Value | Volume |
| $15.38 | $15.40 | $14.40 | $9.160M | 624.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50 | $14.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.55 | 1764 | 2 |
View Market Depth
| Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |